{"id":973525,"date":"2026-06-18T08:03:14","date_gmt":"2026-06-18T12:03:14","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/charles-river-joins-lilly-tunelab-to-optimize-ai-ml-platform-through-nonclinical-testing-expertise\/"},"modified":"2026-06-18T08:03:14","modified_gmt":"2026-06-18T12:03:14","slug":"charles-river-joins-lilly-tunelab-to-optimize-ai-ml-platform-through-nonclinical-testing-expertise","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/charles-river-joins-lilly-tunelab-to-optimize-ai-ml-platform-through-nonclinical-testing-expertise\/","title":{"rendered":"Charles River Joins Lilly TuneLab to Optimize AI\/ML Platform through Nonclinical Testing Expertise"},"content":{"rendered":"<p>        <!--.bwalignc { text-align: center; list-style-position: inside }body {font:normal small Arial,Helvetica,sans-serif;color:#000;background-color:#fff;padding:24px;margin:0;} a img {border:0;} h3 {font-size:medium;color:#000;margin:0 0 1em 0; text-align:center;}-->  <\/p>\n<p class=\"bwalignc\"><b>Charles River Joins Lilly TuneLab to Optimize AI\/ML Platform through Nonclinical Testing Expertise<\/b><\/p>\n<p class=\"bwalignc\"><i>Collaboration supports Charles River\u2019s strategic goals to build deeper client relationships to further modernize R&amp;D through innovative technologies<\/i><\/p>\n<p>WILMINGTON, Mass.&#8211;(<a href=\"http:\/\/www.businesswire.com\">BUSINESS WIRE<\/a>)&#8211;<br \/>\nCharles River Laboratories International, Inc. (NYSE: CRL) announced a collaboration with <a rel=\"nofollow\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Ftunelab.lilly.com%2F&amp;esheet=54555805&amp;newsitemid=20260618961171&amp;lan=en-US&amp;anchor=Lilly+TuneLab&amp;index=1&amp;md5=a097d2fb8476cb33f017a2be87671bff\">Lilly TuneLab<\/a>, a collaborative AI\/ML drug discovery platform created by Eli Lilly and Company (Lilly).<\/p>\n<p>\nTuneLab was created to accelerate biotech innovation by enabling participating companies to access AI\/ML drug discovery models trained on decades of Lilly&#8217;s proprietary research data, in exchange for data contributions that improve model performance through federated learning. Participating companies may use the TuneLab prediction models to more rapidly down-select candidate molecules. Through this collaboration, Charles River will provide nonclinical testing services to TuneLab companies.<\/p>\n<p>\n\u201cThe combination of Charles River\u2019s decades-long expertise in nonclinical testing with TuneLab\u2019s innovative AI\/ML models will support the accelerated development of innovative therapeutics,\u201d said Dr. Namandj\u00e9 N. Bumpus, Chief Science and Innovation Officer, Charles River. \u201cTuneLab\u2019s collaborative AI platform democratizes access to pharma-grade tools, relieving a substantial resource burden for biotechs. By layering in Charles River\u2019s industry-leading hands-on research experience, TuneLab participants have access to additional validation that supports discovery decision-making.\u201d<\/p>\n<p>\nStandardizing protocols with nonclinical testing across the TuneLab ecosystem should enable the AI\/ML models to learn more efficiently from the ongoing contributions, improving the models further and increasing the efficiency of the TuneLab platform.<\/p>\n<p>\nLilly TuneLab is part of Lilly Catalyze360, alongside Lilly Ventures, Lilly Gateway Labs, and Lilly ExploR&amp;D, which together support biotech innovation by providing access to strategic capital, lab space and technology, and research and development capabilities.<\/p>\n<p>\nCharles River remains committed to advancing the validation and acceptance of new approach methodologies (NAMs), including through its Alternative Methods Advancement Project\u2122 (AMAP\u2122) initiative. Together with clients, regulators, and industry, NAMs provide a foundation for a future where more patients gain access to life-saving treatments\u2014safely, swiftly, and with reduced reliance on animal use in research where scientifically appropriate.<\/p>\n<p><b>About the Alternative Methods Advancement Project (AMAP)<\/b><\/p>\n<p>\nThe Alternative Methods Advancement Project (AMAP) is a Charles River-led initiative dedicated to developing New Approach Methodologies (NAMs) and exploring innovative scientific and technological solutions aimed at reducing reliance on traditional animal testing. As we enter the next frontier of drug development, AMAP enables strategic, purpose-driven investment to shape a future in which more patients can access the treatments and medicines they need safely, swiftly, and successfully. AMAP is supported by our global, cross-functional <a rel=\"nofollow\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.criver.com%2Fabout-us%2Fabout-us-overview%2Fnew-approach-methodologies%2Fscientific-advisory-board%3Fregion%3D3601&amp;esheet=54555805&amp;newsitemid=20260618961171&amp;lan=en-US&amp;anchor=Scientific+Advisory+Board&amp;index=2&amp;md5=6f79a2f6e3db8f1b1454052ef466604e\">Scientific Advisory Board<\/a> led by Dr. Namandj\u00e9 N. Bumpus.<\/p>\n<p><b>About Charles River<\/b><\/p>\n<p>\nCharles River provides essential products and services to help pharmaceutical and biotechnology companies, government agencies and leading academic institutions around the globe accelerate their research and drug development efforts. Our dedicated employees are focused on providing clients with exactly what they need to improve and expedite the discovery, early-stage development and safe manufacture of new therapies for the patients who need them. To learn more about our unique portfolio and breadth of services, visit <a rel=\"nofollow\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.criver.com&amp;esheet=54555805&amp;newsitemid=20260618961171&amp;lan=en-US&amp;anchor=www.criver.com&amp;index=3&amp;md5=7495a16064e0c8ca354daa5954215d0b\">www.criver.com<\/a>.<\/p>\n<p><img decoding=\"async\" alt=\"\" src=\"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20260618961171r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\" style=\"width:0;height:0\" \/><span class=\"bwct31415\" \/><\/p>\n<p id=\"mmgallerylink\"><span id=\"mmgallerylink-phrase\">View source version on businesswire.com: <\/span><span id=\"mmgallerylink-link\"><a href=\"https:\/\/www.businesswire.com\/news\/home\/20260618961171\/en\/\" rel=\"nofollow\">https:\/\/www.businesswire.com\/news\/home\/20260618961171\/en\/<\/a><\/span><\/p>\n<p><b>Charles River Investor Contact:<br \/>\n<br \/><\/b>Todd Spencer<br \/>\n<br \/>Corporate Vice President,<br \/>\n<br \/>Investor Relations<br \/>\n<br \/>781.222.6455<br \/>\n<br \/><a rel=\"nofollow\" href=\"mailto:todd.spencer@crl.com\">todd.spencer@crl.com<br \/>\n<\/a><\/p>\n<p><b>Charles River Media Contact:<br \/>\n<br \/><\/b>Amy Cianciaruso<br \/>\n<br \/>Corporate Senior Vice President,<br \/>\n<br \/>Chief Communications Officer<br \/>\n<br \/>781.222.6168<br \/>\n<br \/><a rel=\"nofollow\" href=\"mailto:amy.cianciaruso@crl.com\">amy.cianciaruso@crl.com<\/a><\/p>\n<p><b>KEYWORDS:<\/b> United States North America Massachusetts<\/p>\n<p><b>INDUSTRY KEYWORDS:<\/b> Data Management Biotechnology Technology Health General Health Pharmaceutical Medical Devices Research Software Artificial Intelligence Science<\/p>\n<p><b>MEDIA:<\/b><\/p>\n<table cellpadding=\"3\" cellspacing=\"3\">\n<tr>\n<td><font face=\"Arial\" size=\"2\"><b>Logo<\/b><\/font><\/td>\n<\/tr>\n<tr>\n<td><img decoding=\"async\" src=\"https:\/\/mms.businesswire.com\/media\/20260618961171\/en\/836653\/3\/charles_river_logo.jpg\" alt=\"Logo\" \/><\/td>\n<\/tr>\n<tr>\n<td><font face=\"Arial\" size=\"2\"><\/font><\/td>\n<\/tr>\n<\/table>\n","protected":false},"excerpt":{"rendered":"<p>Charles River Joins Lilly TuneLab to Optimize AI\/ML Platform through Nonclinical Testing Expertise Collaboration supports Charles River\u2019s strategic goals to build deeper client relationships to further modernize R&amp;D through innovative technologies WILMINGTON, Mass.&#8211;(BUSINESS WIRE)&#8211; Charles River Laboratories International, Inc. (NYSE: CRL) announced a collaboration with Lilly TuneLab, a collaborative AI\/ML drug discovery platform created by Eli Lilly and Company (Lilly). TuneLab was created to accelerate biotech innovation by enabling participating companies to access AI\/ML drug discovery models trained on decades of Lilly&#8217;s proprietary research data, in exchange for data contributions that improve model performance through federated learning. Participating companies may use the TuneLab prediction models to more rapidly down-select candidate molecules. Through this collaboration, Charles River will provide nonclinical testing &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/charles-river-joins-lilly-tunelab-to-optimize-ai-ml-platform-through-nonclinical-testing-expertise\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;Charles River Joins Lilly TuneLab to Optimize AI\/ML Platform through Nonclinical Testing Expertise&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-973525","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.8 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Charles River Joins Lilly TuneLab to Optimize AI\/ML Platform through Nonclinical Testing Expertise - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/charles-river-joins-lilly-tunelab-to-optimize-ai-ml-platform-through-nonclinical-testing-expertise\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Charles River Joins Lilly TuneLab to Optimize AI\/ML Platform through Nonclinical Testing Expertise - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"Charles River Joins Lilly TuneLab to Optimize AI\/ML Platform through Nonclinical Testing Expertise Collaboration supports Charles River\u2019s strategic goals to build deeper client relationships to further modernize R&amp;D through innovative technologies WILMINGTON, Mass.&#8211;(BUSINESS WIRE)&#8211; Charles River Laboratories International, Inc. (NYSE: CRL) announced a collaboration with Lilly TuneLab, a collaborative AI\/ML drug discovery platform created by Eli Lilly and Company (Lilly). TuneLab was created to accelerate biotech innovation by enabling participating companies to access AI\/ML drug discovery models trained on decades of Lilly&#8217;s proprietary research data, in exchange for data contributions that improve model performance through federated learning. Participating companies may use the TuneLab prediction models to more rapidly down-select candidate molecules. Through this collaboration, Charles River will provide nonclinical testing &hellip; Continue reading &quot;Charles River Joins Lilly TuneLab to Optimize AI\/ML Platform through Nonclinical Testing Expertise&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/charles-river-joins-lilly-tunelab-to-optimize-ai-ml-platform-through-nonclinical-testing-expertise\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2026-06-18T12:03:14+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20260618961171r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/charles-river-joins-lilly-tunelab-to-optimize-ai-ml-platform-through-nonclinical-testing-expertise\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/charles-river-joins-lilly-tunelab-to-optimize-ai-ml-platform-through-nonclinical-testing-expertise\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Charles River Joins Lilly TuneLab to Optimize AI\\\/ML Platform through Nonclinical Testing Expertise\",\"datePublished\":\"2026-06-18T12:03:14+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/charles-river-joins-lilly-tunelab-to-optimize-ai-ml-platform-through-nonclinical-testing-expertise\\\/\"},\"wordCount\":595,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/charles-river-joins-lilly-tunelab-to-optimize-ai-ml-platform-through-nonclinical-testing-expertise\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&amp;sty=20260618961171r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/charles-river-joins-lilly-tunelab-to-optimize-ai-ml-platform-through-nonclinical-testing-expertise\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/charles-river-joins-lilly-tunelab-to-optimize-ai-ml-platform-through-nonclinical-testing-expertise\\\/\",\"name\":\"Charles River Joins Lilly TuneLab to Optimize AI\\\/ML Platform through Nonclinical Testing Expertise - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/charles-river-joins-lilly-tunelab-to-optimize-ai-ml-platform-through-nonclinical-testing-expertise\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/charles-river-joins-lilly-tunelab-to-optimize-ai-ml-platform-through-nonclinical-testing-expertise\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&amp;sty=20260618961171r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\",\"datePublished\":\"2026-06-18T12:03:14+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/charles-river-joins-lilly-tunelab-to-optimize-ai-ml-platform-through-nonclinical-testing-expertise\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/charles-river-joins-lilly-tunelab-to-optimize-ai-ml-platform-through-nonclinical-testing-expertise\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/charles-river-joins-lilly-tunelab-to-optimize-ai-ml-platform-through-nonclinical-testing-expertise\\\/#primaryimage\",\"url\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&amp;sty=20260618961171r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\",\"contentUrl\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&amp;sty=20260618961171r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/charles-river-joins-lilly-tunelab-to-optimize-ai-ml-platform-through-nonclinical-testing-expertise\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Charles River Joins Lilly TuneLab to Optimize AI\\\/ML Platform through Nonclinical Testing Expertise\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Charles River Joins Lilly TuneLab to Optimize AI\/ML Platform through Nonclinical Testing Expertise - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/charles-river-joins-lilly-tunelab-to-optimize-ai-ml-platform-through-nonclinical-testing-expertise\/","og_locale":"en_US","og_type":"article","og_title":"Charles River Joins Lilly TuneLab to Optimize AI\/ML Platform through Nonclinical Testing Expertise - Market Newsdesk","og_description":"Charles River Joins Lilly TuneLab to Optimize AI\/ML Platform through Nonclinical Testing Expertise Collaboration supports Charles River\u2019s strategic goals to build deeper client relationships to further modernize R&amp;D through innovative technologies WILMINGTON, Mass.&#8211;(BUSINESS WIRE)&#8211; Charles River Laboratories International, Inc. (NYSE: CRL) announced a collaboration with Lilly TuneLab, a collaborative AI\/ML drug discovery platform created by Eli Lilly and Company (Lilly). TuneLab was created to accelerate biotech innovation by enabling participating companies to access AI\/ML drug discovery models trained on decades of Lilly&#8217;s proprietary research data, in exchange for data contributions that improve model performance through federated learning. Participating companies may use the TuneLab prediction models to more rapidly down-select candidate molecules. Through this collaboration, Charles River will provide nonclinical testing &hellip; Continue reading \"Charles River Joins Lilly TuneLab to Optimize AI\/ML Platform through Nonclinical Testing Expertise\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/charles-river-joins-lilly-tunelab-to-optimize-ai-ml-platform-through-nonclinical-testing-expertise\/","og_site_name":"Market Newsdesk","article_published_time":"2026-06-18T12:03:14+00:00","og_image":[{"url":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20260618961171r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/charles-river-joins-lilly-tunelab-to-optimize-ai-ml-platform-through-nonclinical-testing-expertise\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/charles-river-joins-lilly-tunelab-to-optimize-ai-ml-platform-through-nonclinical-testing-expertise\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Charles River Joins Lilly TuneLab to Optimize AI\/ML Platform through Nonclinical Testing Expertise","datePublished":"2026-06-18T12:03:14+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/charles-river-joins-lilly-tunelab-to-optimize-ai-ml-platform-through-nonclinical-testing-expertise\/"},"wordCount":595,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/charles-river-joins-lilly-tunelab-to-optimize-ai-ml-platform-through-nonclinical-testing-expertise\/#primaryimage"},"thumbnailUrl":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20260618961171r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/charles-river-joins-lilly-tunelab-to-optimize-ai-ml-platform-through-nonclinical-testing-expertise\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/charles-river-joins-lilly-tunelab-to-optimize-ai-ml-platform-through-nonclinical-testing-expertise\/","name":"Charles River Joins Lilly TuneLab to Optimize AI\/ML Platform through Nonclinical Testing Expertise - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/charles-river-joins-lilly-tunelab-to-optimize-ai-ml-platform-through-nonclinical-testing-expertise\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/charles-river-joins-lilly-tunelab-to-optimize-ai-ml-platform-through-nonclinical-testing-expertise\/#primaryimage"},"thumbnailUrl":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20260618961171r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en","datePublished":"2026-06-18T12:03:14+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/charles-river-joins-lilly-tunelab-to-optimize-ai-ml-platform-through-nonclinical-testing-expertise\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/charles-river-joins-lilly-tunelab-to-optimize-ai-ml-platform-through-nonclinical-testing-expertise\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/charles-river-joins-lilly-tunelab-to-optimize-ai-ml-platform-through-nonclinical-testing-expertise\/#primaryimage","url":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20260618961171r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en","contentUrl":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20260618961171r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en"},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/charles-river-joins-lilly-tunelab-to-optimize-ai-ml-platform-through-nonclinical-testing-expertise\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Charles River Joins Lilly TuneLab to Optimize AI\/ML Platform through Nonclinical Testing Expertise"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/973525","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=973525"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/973525\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=973525"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=973525"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=973525"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}